我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

派能达胶囊对慢乙肝肝硬化患者外周血象及症状的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2015年03期
页码:
55-57
栏目:
临床研究
出版日期:
2015-06-14

文章信息/Info

Title:
The Effect of Painengda on Peripheral Blood Cell Count and Symptoms of Patients withChronic Hepatitis B and Liver Fibrosis
作者:
余亚平叶蕾高瑞兰△
浙江省中医院,浙江 杭州 310006
Author(s):
YU Yaping YE Lei GAO Ruilan△
Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou 310006, China
关键词:
派能达胶囊 慢性乙型 病毒性肝炎 肝硬化 白细胞 血小板 证候积分
Keywords:
Painengda Hepatitis B chronic Liver fibrosis WBC PLT syndrome integral
分类号:
R256.4
DOI:
-
文献标识码:
A
摘要:
目的〓通过观察派能达胶囊对慢乙肝肝硬化患者外周血象及症状的影响,探讨其是否可增强抗病毒治疗疗效,为临床慢乙肝肝硬化的治疗提供帮助。方法〓60例患者随机分为2组,每组30例,对照组用抗病毒药(拉米夫定100mg/d+阿德福韦酯10mg/d),治疗组加用派能达胶囊(2粒/次,2次/d);派能达胶囊治疗6个月,治疗结束后所有患者继续服用抗病毒药物并随访。比较两组治疗前后的中医证候积分。对病例中伴白细胞减少(<4*109/L)和(或)血小板减少(<100*109/L)的比较治疗前后血细胞水平。结果〓1. 治疗后,治疗组患者的WBC计数较治疗前升高(P<0.05),对照组患者的WBC计数较治疗前也升高(P>0.05),治疗后治疗组的WBC计数高于对照组(P<0.05); 2. 治疗后2组血小板计数较前均有升高,但同组治疗前后比较无统计学差异,两组间比较治疗前后PLT计数也无统计学差异; 3. 2组治疗后证候积分均下降(P<0.05),且治疗后治疗组积分低于对照组(P<0.05)。结论〓派能达胶囊联合抗病毒治疗可提高抗病毒疗效,改善慢乙肝肝硬化患者血细胞减少症,改善患者临床症状,提高生活质量。
Abstract:
Objective To observe the effect of Painengda on peripheral blood cell count and symptoms of patients with Chronic Hepatitis B and Liver fibrosis, explore whether can it strengthen the curative effect of nucleoside analogues, and help in treatment of Chronic Hepatitis B and Liver fibrosis. Methods The selected 60 patients were randomly assigned to two Groups(30 patients in each group), the control group were treated by nucleoside analogues(Lamivudine 100mg and Adefovir 10mg once a day)while the treated group were treated by nucleoside analogues(the same as the control group) and Painengda, which dose was 2 pills twice a day. After 6 months, the treatment of Painengda was stopped, the treatment of nucleoside analogues going on in both of the groups. Then compared syndrome integral of two groups and compared the peripheral blood cell count of patients with low level of WBC(<4×109/L) and(or) PLT(<100×109/L). Results 1. The WBC level in the treated group was obviously enhanced than in the control group(P<0.05); 2. The PLT level raised in each group after therapy, but there were no statistical differences in each group itself or between the two groups; 3. The syndrome integral decreased in both of the two groups after treatment(P<0.05), while the treated group’s lower(P<0.05). Conclusion Painengda can improve the curative effect of nucleoside analogues, increase the count of WBC and PLT and improve the clinical symptoms, creating a better quality of life.

参考文献/References

[1] 杨将领,张斌. 92例ALT持续正常的慢性乙型肝炎患者肝组织病理及HBV-DNA水平与中医证型相关性分析[J]. 云南中医学院学报,2014,12(6):48-51.
[2] 陈君康,朱肖鸿,王树民. 肝郁脾虚型慢性乙型肝炎病理与血清HBV-DNA关系[J]. 云南中医学院学报,2014,37(6):39-41.
[3] 徐克成,危北海,姚希贤,等. 慢性乙型肝炎当代中西医结合治疗[J]. 中国中西医结合脾胃病杂志,2000,8(1):3-6.
[4] 中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 肝脏,2005,10(4):348-357.
[5] 马逢顺,高瑞兰,林筱洁,等. 升血灵胶囊(人参总皂苷)治疗免疫性血小板减少症的临床研究[J]. 浙江中医药大学学报,2012,36(2):137-140.
[6] 叶宝东,孙成龙,林胜云,等. 升血灵联合环孢霉素A治疗重型再生障碍性贫血临床观察[J]. 世界中西医结合杂志,2010,5(2):133-136.
[7] SHAO Ke-ding,ZHOU Yu-hong,SHEN Yi-ping,et al. Treatment of 37 Patients with Refractory Idiopathic Thrombocytopenic Purpura by Shengxueling(SXL)[J]. Chin J Integr Med,2001,13(1):33-36.
[8] 魏守超,杜爱萍. 升血灵冲剂治疗肿瘤患者化疗所致骨髓抑制40例[J]. 中国民间疗法,2003,11(5):57-58.
[9] 周郁鸿,郭宇,胡致平,等. 升血灵胶囊联合ALG/ATG和CSA治疗重型再生障碍性贫血疗效的临床观察[J]. 浙江中医药大学学报,2009,33(2):175-177.
[10] 杨晶. 探讨慢性乙型肝炎合并白细胞减少症的病因诊断及分析[J]. 中国社区医师,2010,12(5):60.
[11] 李军生,苏立稳,孟明辉. 中药联合脾动脉栓塞术治疗肝硬化脾功能亢进54例[J]. 中西医结合肝病杂志,2011,21(5):306-307.
[12] 符布清,孙延涛,高峰,等. 肝硬化患者血液细胞学指标的变化研究[J]. 中国现代医药杂志,2006,8(11):15-16.
[13] 张导文,刘惠敏. 毫米波辅助治疗乙肝肝硬化合并白细胞及血小板减少疗效观察[J]. 临床医学,2006,26(6):1-2.
[14] 陆建春,吴国祥,周胜生,等. 拉米夫定治疗活动型乙肝后肝硬化外周血细胞减少的研究[J]. 中原医刊,2003,30(23):49-50.
[15] 刘卉,曹祥梦,燕奎华,等. 恩替卡韦治疗失代偿期乙肝肝硬化临床疗效分析[J]. 实用临床医药杂志,2011,15(17):113-115.
[16] 王庆治,王素娟,杜鹏程,等. 拉米夫定联合阿德福韦酯治疗乙肝肝硬化失代偿期 57例临床观察[J]. 临床医学,2012,32(8):28-29.

备注/Memo

备注/Memo:
* 基金项目: 浙江省中医药科学研究基金计划项目(2012ZA041) 收稿日期: 2015 - 03 - 16 作者简介: 余亚平(1983-),女,浙江天台人,主治医师,主要从事中西医结合感染病的研究及临床工作。△通信作者:高瑞兰,E-mail:gaoruilan@126.com
更新日期/Last Update: 2015-06-15